Market LIVE
Published markets; coverage varies by country
Product profile · United States

CHILDREN'S ALLEGRA ALLERGY

 ·  Patent Litigation & Settlement History ↓

IngredientFEXOFENADINE HYDROCHLORIDE
Application typeNDA
Application201373
Product001
Dosage formSUSPENSION
RouteORAL
Strength30MG/5ML
Approval date2011-01-24
Marketing statusOver-the-counter
Status event—
ApplicantCHATTEM SANOFI
Product source

Current GenericRadar decision

Year2011
SelectionEXCLUDED
ReviewFINAL
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

Current official Orange Book exact product Type=OTC. Excluded under guideline section 4 OTC-only rule. Historical prescription status and switch effective date are not asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
89330972030-08-02DP ————
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
201311 / 001FINAL_APPROVAL · FINAL_APPROVED2012-07-25—P AND L DEVELOPMENT LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203330 / 001FINAL_APPROVAL · FINAL_APPROVED2014-11-18—P AND L DEVELOPMENT LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203330 / 002FINAL_APPROVAL · FINAL_APPROVED2014-11-18—P AND L DEVELOPMENT LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208123 / 001FINAL_APPROVAL · FINAL_APPROVED2017-11-09—TARO PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208123 / 002FINAL_APPROVAL · FINAL_APPROVED2017-11-09—TARO PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213466 / 001FINAL_APPROVAL · FINAL_APPROVED2023-05-23—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 6 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
201311 / 001P AND L DEVELOPMENT LLCFINAL_APPROVAL · FINAL_APPROVED2012-07-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203330 / 001P AND L DEVELOPMENT LLCFINAL_APPROVAL · FINAL_APPROVED2014-11-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203330 / 002P AND L DEVELOPMENT LLCFINAL_APPROVAL · FINAL_APPROVED2014-11-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208123 / 001TARO PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2017-11-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208123 / 002TARO PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2017-11-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213466 / 001AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2023-05-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
PRODUCT_STATUS—EXCLUSION_BASISExact application/product matched to current Orange Book Type=OTC; no patent or generic conclusion inferred.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.